MDSpire - MDSpire Home
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The Medicine Maker

  • October 21, 2026
CAR NK Cells Target Cancer and Autoimmunity
  • October 21, 2026
  • 2 min

Objective: To develop lipid nanoparticles that deliver mRNA to natural killer (NK) cells in vivo and assess their effects in mouse models of cancer and autoimmu

...more
2 min

MDSpire News

  • October 21, 2026
1 in 4 US Army men may screen low for testosterone
  • Andrea Surnit
  • October 21, 2026
  • 3 min
  1. In a cross-sectional analysis of 479 active-duty US Army men, 25.7% had morning testosterone concentrations below 300 ng/dL and 14.7% were below 264 ng/dL.
  2. The estimates corresponded to approximately 100,691 men below 300 ng/dL and 57,788 below 264 ng/dL across the active-duty Army.
  3. Low testosterone concentrations were more common among men aged 30 years or older, and age and BMI were associated with higher odds of concentrations below either threshold.
  4. Among nonobese men aged 19 to 39 years, 9.7% had testosterone concentrations below 264 ng/dL, corresponding to an estimated 23,115 men Army-wide.
  5. The authors cautioned that screening estimates do not represent hypogonadism prevalence; the study relied on a single measurement and had a cross-sectional design.
...more

MDSpire News

  • October 21, 2026
PMOS-dementia link may reflect metabolic risks
  • Andrea Surnit
  • October 21, 2026
  • 4 min

Objective: Review evidence on associations between polyendocrine metabolic ovarian syndrome (PMOS/PCOS) and cognitive function, brain changes, Alzheimer’s disea

...more

The Pathologist

  • October 21, 2026
Preparing Pathology for the Cancer Surge
  • Jessica Allerton
  • October 21, 2026
  • 8 min
  1. Cancer diagnoses are expected to exceed 2 million annually in the United States, increasing laboratory volumes and the complexity of pathology workups.
  2. Earlier detection may bring more subtle or borderline lesions into the diagnostic pathway, requiring pathologists to integrate morphology, molecular profiling, germline testing, and other findings.
  3. Laboratories should design workflows alongside new tests, including automation, digital case management, system interoperability, and tissue stewardship.
  4. Digital pathology can enable remote specialist consultation and distributed case review, helping laboratories share expertise across locations and time zones.
  5. Integrating digital pathology, genomics, AI, and clinical information can support pathologists’ judgment, while turnaround time depends on the entire pathway from test order to accessible reporting.
...more

MDSpire News

  • October 21, 2026
FDA approves liquid cevimeline for Sjögren’s disease
  • Mouj Hijazi
  • October 21, 2026
  • 3 min
  1. The FDA approved oral solution cevimeline hydrochloride for treating dry mouth in adults with Sjögren’s disease.
  2. The liquid formulation offers an alternative to existing cevimeline capsules for patients who have difficulty swallowing them.
  3. The approval relied in part on existing safety and efficacy data for cevimeline capsules and did not require a full-scale clinical development program.
  4. No new randomized efficacy trial or comparative data were reported, and the approval does not establish superior symptom relief with the oral solution.
  5. Cosette expects the oral solution to be commercially available in the United States by the end of 2026.
...more

The Pathologist

  • October 21, 2026
CRISPR Test Accelerates Mycobacterial Diagnosis
  • October 21, 2026
  • 2 min

Objective: The article describes CANDI, a CRISPR-based platform designed to identify mycobacterial species more rapidly and distinguish tuberculosis from nontub

...more
2 min

The Analytical Scientist

  • October 21, 2026
Climate Models May Miss Marine Aerosols
  • October 21, 2026
  • 3 min

Objective: Assess whether climate-model representations of marine primary organic aerosols capture their observed particle sizes, abundance, and potential cloud

...more
2 min

The Analytical Scientist

  • October 21, 2026
Mass Spectrometry Imaging Maps Intact Proteins in Tissue
  • October 21, 2026
  • 3 min

Objective: The article examines the objective, findings, and clinical context described in Mass Spectrometry Imaging Maps Intact Proteins in Tissue. Approach: S

...more

MDSpire News

  • October 21, 2026
FDA clears new generic weekly menopause patch
  • Mouj Hijazi
  • October 21, 2026
  • 2 min

Objective: The article examines the objective, findings, and clinical context described in FDA clears new generic weekly menopause patch. Approach: Product: Zyd

...more
2 min

MDSpire News

  • October 21, 2026
Doctor convicted in 2 million–pill stimulant scheme
  • Teraya Smith
  • October 21, 2026
  • 3 min

Objective: The article examines the objective, findings, and clinical context described in Doctor convicted in 2 million–pill stimulant scheme. Approach: Case:

...more
2 min

Baptist Health South Florida

  • October 21, 2026
Rising Endometrial Cancer Incidence: Clinical Priorities in Evaluation and Management
  • October 21, 2026
  • 6 min

Objective: The article examines the objective, findings, and clinical context described in Rising Endometrial Cancer Incidence: Clinical Priorities in Evaluati

...more
3 min

MDSpire News

  • October 21, 2026
FDA approves first antisense therapy for hepatitis B
  • Mouj Hijazi
  • October 21, 2026
  • 3 min
  1. The FDA approved bepirovirsen as the first antisense oligonucleotide therapy for chronic hepatitis B in eligible adults without cirrhosis.
  2. Eligible adults must have received nucleos(t)ide analogue therapy for at least 6 months, have suppressed HBV DNA, and have HBsAg levels of 3,000 IU/mL or less.
  3. Bepirovirsen is given by subcutaneous injection alongside existing antiviral therapy for up to 24 weeks and targets HBV RNA to reduce viral protein production.
  4. In pooled phase 3 trial results, functional cure occurred in 19% of bepirovirsen recipients and 0% of placebo recipients after treatment discontinuation.
  5. Bepirovirsen carries boxed warnings for serious liver reactions and low platelet counts, including potentially life-threatening bleeding.
...more

The Medicine Maker

  • October 21, 2026
Prime Editing Corrects GATA2 Deficiency in Patient Stem Cells
  • October 21, 2026
  • 3 min

Objective: To test whether prime editing could repair a disease-causing GATA2 mutation in patient-derived blood stem and progenitor cells. Approach: Editing str

...more
2 min

The Medicine Maker

  • October 21, 2026
Analytical Champions: Robert Wethman
  • October 21, 2026
  • 7 min
  1. Robert Wethman says analytical science supports manufacturing with robust methods and increasingly shapes development and manufacturing timelines and outcomes.
  2. He identifies simultaneous growth in molecular, modality, and process complexity, alongside compressed timelines, as a major source of analytical bottlenecks.
  3. Wethman says real-time spectroscopy implementation requires early collaboration, shared goals, high-quality data, and attention to operational impact and support.
  4. He reports that at-line spectroscopy has provided a practical bridge at BMS-owned and CDMO sites while teams evaluate full real-time monitoring.
  5. Wethman cites regulated-environment readiness among instrument vendors and expanding AI-based modeling as important developments in analytical manufacturing.
...more

Jama Network Open

  • October 21, 2026
Wait Times for Neurology Appointments in the Cognitive Care Pathway
  • Tabasa Ozawa
  • Soeren Mattke
  • October 21, 2026

Objective: The article examines the objective, findings, and clinical context described in Wait Times for Neurology Appointments in the Cognitive Care Pathway.

...more
2 min

Jama Network Open

  • October 21, 2026
Supporting Families of Injured Children Before Interhospital Transfer Requires More Than Telemedicine
  • Margaret Samuels-Kalow
  • Kenneth A. Michelson
  • October 21, 2026

Objective: The article examines the objective, findings, and clinical context described in Supporting Families of Injured Children Before Interhospital Transfer

...more
2 min

Nature Medicine

  • October 21, 2026
Author Correction: Phase 3 STOP-HS1 and STOP-HS2 Trials of Povorcitinib for Hidradenitis Suppurativa: Randomized, Double-Blind, Placebo-Controlled Studies
  • Martina L. Porter
  • Antonio Martorell
  • Christopher J. Sayed
  • Falk G. Bechara
  • Hadar Lev-Tov
  • Jennifer L. Hsiao
  • John W. Frew
  • Ziad Reguiaï
  • Melinda J. Gooderham
  • Noah Goldfarb
  • Hessel H. van der Zee
  • Veronique del Marmol
  • Angelo V. Marzano
  • Benjamin D. Ehst
  • Lindsay S. Ackerman
  • Koremasa Hayama
  • Chenwei Tian
  • Jennifer Kelley
  • Huiling Zhen
  • Joslyn S. Kirby
  • Kurt Brown
  • Leandro L. Santos
  • Christos C. Zouboulis
  • October 21, 2026

Objective: The correction updates patient disease-duration data, Figure 1 discontinuation footnotes, Table 2 annotations, Extended Data Figure 5 presentation, a

...more
2 min

Jama Network Open

  • October 21, 2026
Mailed Fecal Immunochemical Testing: Moving From Efficacy to Real-World Implementation
  • Kevin Selby
  • Ekaterina Plys
  • Bianca Albers
  • October 21, 2026

Objective: The article examines the objective, findings, and clinical context described in Mailed Fecal Immunochemical Testing: Moving From Efficacy to Real-Wor

...more
2 min